Martin Smithmyer

Founder, CEO of Americord, the leading umbilical cord blood stem cell cryostorage company in the United States

[Martin Smithmyer @msmithmyer]

I am excited to announce Lyos Inc., our newest injectable regenerative medicine biotech platform. This platform is built on over 18 years of cord blood science at Americord. We are currently preparing for FDA submission and are targeting multi-billion dollar markets in hair, skin, orthopedics, and wound healing. We are seeking partnerships and connections to accelerate commercialization. For those interested in learning more about what we are building, feel free to reach out. Visit us at https://t.co/K5KUhldwGl

[Martin Smithmyer @msmithmyer]

@StaafJackie @TomBevanRCP Source?

[sliccmic 𖤐 @sliccmic]

just let it go at this point

[Martin Smithmyer @msmithmyer]

Florida and Utah just opened exciting new doors for regenerative medicine, explicitly allowing therapies using donated placenta and cord-derived stem cells!

Florida’s HB 1617 (2025) focuses on orthopedics, pain, and wound treatments, requiring high-quality lab accreditation and strict patient transparency.

Utah’s SB0199 (2024) broadly supports ethical placental-derived therapies across many specialties, prioritizing clear patient disclosures and consent.

Great news for Americord—these laws enable expanded partnerships to deliver life-enhancing stem cell products safely and legally.

[Martin Smithmyer @msmithmyer]

@JordanChariton @RFKJr_Official

[vittorio @IterIntellectus]

i asked gpt4.5 what’s a deep truth that most people are not aware of
and then i kept asking

1. discomfort isn't just inevitable; it's essential. chase friction relentlessly.

[Martin Smithmyer @msmithmyer]

@LewisWnLP Cro

[Bill Ackman @BillAckman]

Incredible.

[Martin Smithmyer @msmithmyer]

@KashPatelX Agree

[Martin Smithmyer @msmithmyer]

@OfeliaLamensky @elonmusk lol what did Trump offer him for the endorsement, power and money.

[Martin Smithmyer @msmithmyer]

https://t.co/FpcW3cr4mu

[Martin Smithmyer @msmithmyer]

@elonmusk Same is happening here on X @elonmusk. Zero positive Harris posts show up. You have more credibility is you’re honest.

[Martin Smithmyer @msmithmyer]

@jasondebolt @elonmusk Not true. Watched it on Sunday and still working today.

[Martin Smithmyer @msmithmyer]

Trying out Grok. Seems accurate.

Umbilical cord blood stem cells have become a focal point of regenerative medicine and stem cell research due to their unique properties and potential applications. Here are some surprising facts and state-of-the-art developments:

1. **Disease Treatment**: Initially used primarily for treating blood diseases such as leukemia and lymphoma through bone marrow transplantation, umbilical cord blood stem cells are now being explored for treating a variety of genetic, autoimmune, and degenerative disorders. Conditions like type 1 diabetes, cerebral palsy, and even certain types of hearing loss are under investigation.

2. **Neurological Applications**: Recent studies have shown potential in using these cells to treat neurological disorders. For instance, there's ongoing research into their use for neurodegenerative diseases like Parkinson's and Alzheimer's, where the stem cells might help replace lost cells or modulate the immune response to reduce disease progression.

3. **Cardiac Repair**: There's exciting research into using cord blood stem cells for heart repair after myocardial infarction. These cells can potentially differentiate into heart muscle cells or stimulate the heart's own repair mechanisms, which could revolutionize treatments for heart disease.

4. **Personalized Medicine**: The idea of banking one's own cord blood at birth for potential future use has led to a new field in personalized regenerative medicine. This personal biobanking allows for autologous stem cell transplantation, reducing the risk of rejection.

5. **Immunomodulatory Effects**: Cord blood stem cells have shown remarkable capabilities in modulating the immune system. This property is being harnessed for treating conditions like Crohn's disease, multiple sclerosis, and type 1 diabetes by potentially reprogramming or calming overactive immune responses.

6. **Expansion Techniques**: One major limitation of cord blood stem cells is the low number of stem cells in each unit. However, advancements in stem cell expansion technologies are now allowing for the growth of these cells in culture, potentially making them as viable as bone marrow for adult transplants.

7. **Gene Editing**: The integration of CRISPR and other gene editing technologies with cord blood stem cells opens up possibilities for correcting genetic defects before or after transplantation. This could lead to treatments for genetic disorders by editing out mutations directly in the stem cells.

8. **Ethical and Legal Frameworks**: The use of umbilical cord blood, unlike embryonic stem cells, does not involve ethical dilemmas related to embryo destruction, making it more widely acceptable for research and clinical use. This has led to a robust legal and ethical framework supporting its use in many countries.

9. **Global Cord Blood Banks**: There's been a significant increase in the establishment of public and private cord blood banks worldwide, aiming to create a diverse pool of stem cells for matching donors with patients needing transplants, which has improved the accessibility and success rates of these treatments.

10. **Future Prospects**: The field is moving towards developing "off-the-shelf" stem cell products derived from cord blood, which could be used for emergency treatments without the need for matching, potentially revolutionizing emergency medical care.

These developments illustrate the vast potential of umbilical cord blood stem cells, pushing the boundaries of what's possible in regenerative medicine and offering hope for treatments or cures for many currently incurable conditions.